Abbott Laboratories $ABT Stake Boosted by State Street Corp

State Street Corp increased its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,431,110 shares of the healthcare product maker’s stock after buying an additional 504,876 shares during the period. State Street Corp’s holdings in Abbott Laboratories were worth $8,047,837,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. boosted its position in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after acquiring an additional 6,769,518 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Abbott Laboratories during the 2nd quarter worth approximately $1,603,607,000. Deutsche Bank AG raised its position in shares of Abbott Laboratories by 18.6% in the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock worth $1,515,963,000 after acquiring an additional 2,614,965 shares in the last quarter. Legal & General Group Plc bought a new position in shares of Abbott Laboratories in the 2nd quarter worth approximately $1,082,524,000. Finally, Flossbach Von Storch SE purchased a new position in shares of Abbott Laboratories in the 2nd quarter valued at approximately $902,938,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Mary Moreland sold 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the transaction, the executive vice president owned 100,791 shares of the company’s stock, valued at $11,691,756. This trade represents a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.46% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ABT shares. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Rothschild & Co Redburn raised Abbott Laboratories from a “neutral” rating to a “buy” rating and upped their price target for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Barclays initiated coverage on Abbott Laboratories in a report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price objective for the company. UBS Group lowered their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Finally, Robert W. Baird boosted their target price on shares of Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a report on Thursday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.04.

View Our Latest Research Report on Abbott Laboratories

Abbott Laboratories News Roundup

These are some of the ABT news items that stood out recently:

  • Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, citing a more favorable outlook for the company. The higher rating is a potential bullish catalyst. Article
  • Positive Sentiment: Abbott initiated the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to improve valve deployment; successful development could strengthen Abbott’s cardiovascular device pipeline, though clinical and regulatory outcomes remain uncertain. Article
  • Neutral Sentiment: Articles noting that ABT is up 1.3% since its last earnings report revisit the results and look to earnings estimates for clues, but provide no specific new estimate revisions or fresh financial results. Article

Abbott Laboratories Price Performance

Shares of ABT opened at $102.96 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $129.85. The firm’s 50-day simple moving average is $103.91 and its two-hundred day simple moving average is $101.66. The stock has a market cap of $178.32 billion, a PE ratio of 38.42, a price-to-earnings-growth ratio of 1.88 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The firm had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. During the same period last year, the business earned $1.30 earnings per share. The business’s revenue was up 14.5% on a year-over-year basis. Analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 16th. Investors of record on Thursday, October 15th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Featured Articles

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.